New Research

| Document Preview

IDC MarketScape: Worldwide Life Science Sales and Marketing Strategic Consulting Services 2023 Vendor Assessment

Mar-23 DOC # US50407723 IDC DecisionScape

Authors:

• Michael Townsend

This IDC study provides an assessment of 12 vendors offering strategic consulting solutions for sales and marketing processes in the life science industry. Digital transformation is occurring at a rapid pace in life science companies, including in the sales and marketing space. Internal and external sources of data are being collected in the cloud, and this information is being leveraged by sales and marketing groups to improve speed, efficiency, and effectiveness in reaching customers, including both healthcare providers and patients. Tools such as artificial intelligence (AI), advanced analytics, and orchestration of multiple tasks and roles utilizing data from multiple sources are accelerating change in 2023 and beyond and helping expand the scope of business processes suitable for outsourcing to qualified vendors.

Mike Townsend, research director for Life Science Commercial Strategies at IDC Health Insights, says, "Life science companies are embracing digital transformation efforts within sales and marketing, which can connect stakeholders such as sales representatives, marketing and medical affairs executives, doctors, patients, and payers using a wide variety of digital technologies, including AI, cloud computing, mobile technology, and social media and analytics, and leveraging a host of internal and external data sources. Highly experienced strategic consulting vendors are offering increasingly sophisticated business models for processes leveraging these technologies while allowing these companies to focus on their core competencies. Life science companies will continue to see improved outcomes, growth, and productivity as they free their organizations to focus on core innovation and business cases, using these offerings to improve outcomes for doctors and patients alike."

| Document Preview

Medidata NEXT 2022: Solving the Impossible

Dec-22 DOC # US49893022 Insight

Authors:

• Nimita Limaye
• Michael Townsend

This IDC Perspective reviews the industry analyst event recently hosted by Medidata (a Dassault Systemes [DS] company) from November 15 to 16, 2022, in New York. It was addressed by Life Sciences and Healthcare Sector Board Chairman, DS, Tarek Sherif; co-CEOs of Medidata (Rama Kondru and Sastry Chilukuri); and the CEO of Patient Cloud (Anthony Costello), as well as Medidata's leadership, partners, and customers who outlined the new offerings and the strategic road map for Medidata in life sciences.

"As technology adoption continues to scale rapidly in the life sciences industry, the industry and technology providers continue to innovate; pharmas and biotechs are looking for solutions that will drive quality and compliance, accelerate time to market, and weave in both a site-centric and a patient-centric focus. Technology solutions that power decentralized clinical trials, that drive diversity and equity, that improve access, that integrate a risk-based quality management strategy, and that drive interoperability will serve as differentiators and define the pace of innovation for the life sciences industry," says Dr. Nimita Limaye, research vice president, Life Sciences R&D Strategy and Technology at IDC Health Insights.

"Consolidated clinical trial results, augmented by real-world data and patient and provider insights, can help construct rich patient journey experiences that help life sciences companies and healthcare providers find patients who can benefit from innovative therapies and result in improved health outcomes and better knowledge sharing between researchers, medical affairs experts, providers, and patients," says Michael Townsend, research director, Life Sciences Commercial Strategies at IDC Health Insights.

| Document Preview

Life Science Revenue Management in the Cloud, 2022

Dec-22 DOC # US49929722 Presentation

Authors:

• Michael Townsend

This IDC Survey Spotlight analyzes trends and deployment plans based on results from IDC's Industry CloudPath Survey (April 2022) and IDC's Life Sciences DX Survey (March 2022). Life science companies are increasingly deploying their revenue management solutions in the cloud.

| Document Preview

Deployment of AI in Life Science Commercial Use Cases, 2022

Dec-22 DOC # US49938422 Presentation

Authors:

• Michael Townsend

This IDC Survey Spotlight analyzes deployment of AI in selected life science commercial applications and use cases, based on responses in IDC's Industry AI Path Survey, September 2022.

| Document Preview

State of the Market: Health and Life Sciences — Inflation Impact on IT Spending and the Cloud

Nov-22 DOC # US49812322 Presentation

Authors:

• Lynne Dunbrack
• Jennifer Eaton
• Nino Giguashvili
• Nimita Limaye
• Federico Mayr
• Silvia Piai
• Jeff Rivkin
• Mutaz Shegewi
• Michael Townsend
• Manoj Vallikkat

This IDC Tech Buyer Presentation delves deeper into the impact of inflation on healthcare and life science organizations and includes a discussion of the looming recession. Our analysis also offers IDC's outlook on IT spending and global economics sentiments gleaned from IDC's Future of Enterprise Resiliency and Spending (FERS) Survey.

Analysts across IDC Insights evaluated the impact of eight inflation triggers on their respective industries: supply chain constraints, localized labor shortages, raw materials and component costs, salary increases, tariffs and fiscal policy, energy costs, interest rates, and business margins.

"Inflation is leading health and life sciences organizations to prioritize investments in technologies such as cloud, AI/ML, automation, and advanced analytics, which reduce costs; improve efficiency, productivity, and decision making; and address labor shortages and supply chain constraints." — Lynne A. Dunbrack, group vice president, IDC Health Insights

| Document Preview

IDC FutureScape: Worldwide Healthcare Industry 2023 Predictions

Oct-22 DOC # US48587222 IDC DecisionScape

Authors:

• Mutaz Shegewi
• Adriana Allocato
• Lynne Dunbrack
• Jennifer Eaton
• Nino Giguashvili
• Jason Leigh
• Leon Xiao
• Nimita Limaye
• Silvia Piai
• Nikola Ristivojevich
• Jeff Rivkin
• Michael Townsend
• Manoj Vallikkat
• Federico Mayr

This IDC study provides executives across the globe with actionable insights and analysis for future healthcare industry scenarios.

"The 2023 worldwide healthcare industry predictions focus on the major storms of disruption for the foreseeable future, big tech flips, and how healthcare organizations can prepare for and respond to them," says Mutaz Shegewi, research director, IDC Health Insights. "Technological strategies and capabilities will determine how healthcare organizations navigate the aftereffects of the global COVID-19 pandemic combined with the impact of everything from inflationary pressures to supply chain constraints, labor and skills shortages, the Russia-Ukraine War, and other geopolitical threats. Healthcare organizations also face escalating cybersecurity risks, shifting care models, and an ongoing need to strive for service excellence while addressing broader, systemic challenges. Opportunities present alongside each challenge; however, healthcare organizations must act quickly because the next five years will prove that the storms are not temporary but lasting and interwoven."

| Document Preview

IDC FutureScape: Worldwide Life Sciences 2023 Predictions

Oct-22 DOC # US48585622 IDC DecisionScape

Authors:

• Nimita Limaye
• Lynne Dunbrack
• Nino Giguashvili
• Silvia Piai
• Michael Townsend
• Manoj Vallikkat

This IDC study discusses the top 10 predictions for the life science industry for 2023.

"The 2023 worldwide life science industry predictions focus on the explosion of an ecosystem of digital-native innovators. They are powering a precision medicine strategy, fueling the increased confluence between healthcare and life sciences, scaling sustainability by design initiatives driven by the increasing importance of ESG, and focusing on persistent immersive experiences, led by an extreme obsession with 'data centricity' and 'patient centricity,'" says Dr. Nimita Limaye, research VP, Life Sciences R&D Strategy and Technology at IDC Health Insights.

| Document Preview

Life Science Digital Transformation Business Drivers, 2022

Oct-22 DOC # US49740922 Presentation

Authors:

• Michael Townsend

This IDC Survey Spotlight examines life science digital transformation business drivers for 2022.

Life science companies are investing in digital transformation to improve processes and engagement throughout their business. In IDC's March 2022 Life Sciences DX Survey, respondents rated the importance of business drivers for their digital transformation initiatives in various industry processes and their spending plans for 2022.

| Document Preview

Health Data Platforms in Life Science Digital Transformation, 2022

Sep-22 DOC # US49708322 Presentation

Authors:

• Michael Townsend

This IDC Survey Spotlight features data from IDC's March 2022 Life Sciences DX Survey, is which respondents rated the importance of health data platforms to their organizations from digital transformation initiatives in various industry processes and their spending plans for 2022. Life science companies are embracing health data platforms in their digital transformation initiatives.

| Document Preview

IDC's Worldwide Digital Transformation Use Case Taxonomy, 2022: Life Sciences

Jul-22 DOC # US49278522 Study

Authors:

• Nimita Limaye
• Michael Townsend

This IDC study discusses how digital transformation accurately characterizes the life science industry's ongoing efforts to transform itself as it seeks to find new paths to innovation, optimize operational efficiency and effectiveness, and regain long-term sustainability. As in other industries, the digital transformation journey begins with a common definition of the mission, strategic priorities, and programs so that individual projects or use cases can better align with a life science company's overall goals and objectives.

"Digital transformation continues to transform patient and HCP engagement and fuel innovation in the life science industry. With the increasing adoption of newer technologies such as federated learning platforms, prescription digital therapeutics, and the metaverse, including AR, VR, and MR, it is essential to have a clear understanding of the digital taxonomy for life sciences and to be cognizant of the use cases where these disruptive technologies are being applied," says Dr. Nimita Limaye, research VP, Life Science R&D Strategy and Technology, IDC Health Insights.

"Digital transformation in the life science industry is moving forward rapidly. 3rd Platform technologies such as cloud, mobile, big data and analytics, and social data are already woven into the life science commercial arena. Emerging technologies like AI and RPA are accelerating productivity for commercial teams by maximizing message impact and relevance while reducing duplicate or confusing interactions with HCPs. In life science supply chains, IoT networks and platforms are enabling tracking and monitoring of sensitive and rare biologic drugs, allowing rapid deployment to patients in critical need around the globe. From the manufacturing floor to doctors' offices, digital technology is improving quality, efficiency, and patient experience," says Michael Townsend, research director, Commercial Life Sciences, IDC Health Insights.

| Document Preview

IDC Health Insights' Knowledge-Based Medicine: Digital Transformation in Life Sciences, 2022

Jun-22 DOC # US49300622 Presentation

Authors:

• Nimita Limaye
• Michael Townsend

This IDC Tech Buyer Presentation identifies the digital transformation (DX) use cases associated with life sciences strategies and provides guidance on how to prioritize them to develop a DX road map.

| Document Preview

Life Sciences Commercial Digital Transformation Use Cases — Build or Buy?

Jun-22 DOC # US49279622 Presentation

Authors:

• Michael Townsend

This IDC Survey Spotlight uses data from IDC's Life Sciences DX Survey to illustrate trends and strategies relating to build versus buy decisions for 11 commercial use cases. IDC Health Insights conducted this survey of over 200 IT and line-of-business (LOB) executives at life science companies to understand the current approaches to digital transformation (DX). Vendors may include either software or service providers.

| Document Preview

Benefits of Digital Transformation in Life Science Commercial Processes, 2022

Jun-22 DOC # US49237422 Presentation

Authors:

• Michael Townsend

This IDC Survey Spotlight highlights the benefits of digital transformation in life science commercial processes. Life science companies are benefiting from digital transformation initiatives in their commercial processes. In IDC's Life Sciences DX Survey, March 2022, respondents rated the benefits to their organizations from digital transformation initiatives in various industry processes.